Avantor Investor Conference Presentation Deck
Combined platform is stronger than ever
Organic lab
growth
Bioproduction
customers
Presence in top 20
biologic drugs
Navantor™
LEGACY 1
2-3%
-2,000
~80%
avantor™ 2
4-5%
-9,000
~85%
1. Legacy refers to: organic lab growth - average organic revenue growth of legacy VWR from 2010-2017,
bioproduction customers - legacy Avantor bioproduction customers in 2017, presence in top 20 biologic
drugs legacy Avantor presence in 2017 from Evaluate Pharma.
2. Avantor refers to: organic lab growth - data of combined entity from 2018-2022E, bioproduction
customers - combined entity in 2022E, presence in top 20 biologic drugs - combined entity presence in
2022 from Evaluate Pharma.
3. Comparing legacy Avantor bioproduction sales in 2017 vs. 2022E bioproduction sales.
4X
Growth in
bioproduction
revenue³
41st Annual J.P. Morgan Healthcare Conference
10View entire presentation